Relapsed and refractory acute myeloid leukemia (AML) is a devastating diagnosis with a very low five-year survival rate. Fortunately, researchers are constantly exploring new and improved treatment options. This article explores the potential of gemtuzumab ozogamicin (GO) for patients with relapsed/refractory AML.
Gemtuzumab Ozogamicin (Mylotarg, Pfizer) is an anti-CD33 antibody-drug conjugate. This means it targets a protein called CD33, found on the surface of many AML cells. The antibody delivers a chemotherapy drug directly to the cancer cells, potentially increasing its effectiveness while minimizing side effects on healthy tissues.
A large majority of AML diagnoses express the CD33 antigen. Gemtuzumab ozogamicin is an anti-CD33 monoclonal antibody. It is “FDA approved for patients with AML who cannot tolerate intensive chemotherapy, and additionally received FDA approval in the RR-AML setting on the basis of a modest complete response (CR) rate of 26%.”
Gemtuzumab ozogamicin is optimal for newly diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients 1 month and older and adults and children who are 2 years old or older, and who have CD33-positive AML that is relapsed or refractory.
Several clinical trials are investigating the effectiveness and safety of GO combined with other treatments for relapsed/refractory AML. Here are some ongoing and completed trials:
To continue exploring open clinical trials for AML patients, use the Healthtree's Clinical Trial Finder HERE
CREATE A FREE HEALTHTREE ACCOUNT
Relapsed and refractory acute myeloid leukemia (AML) is a devastating diagnosis with a very low five-year survival rate. Fortunately, researchers are constantly exploring new and improved treatment options. This article explores the potential of gemtuzumab ozogamicin (GO) for patients with relapsed/refractory AML.
Gemtuzumab Ozogamicin (Mylotarg, Pfizer) is an anti-CD33 antibody-drug conjugate. This means it targets a protein called CD33, found on the surface of many AML cells. The antibody delivers a chemotherapy drug directly to the cancer cells, potentially increasing its effectiveness while minimizing side effects on healthy tissues.
A large majority of AML diagnoses express the CD33 antigen. Gemtuzumab ozogamicin is an anti-CD33 monoclonal antibody. It is “FDA approved for patients with AML who cannot tolerate intensive chemotherapy, and additionally received FDA approval in the RR-AML setting on the basis of a modest complete response (CR) rate of 26%.”
Gemtuzumab ozogamicin is optimal for newly diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients 1 month and older and adults and children who are 2 years old or older, and who have CD33-positive AML that is relapsed or refractory.
Several clinical trials are investigating the effectiveness and safety of GO combined with other treatments for relapsed/refractory AML. Here are some ongoing and completed trials:
To continue exploring open clinical trials for AML patients, use the Healthtree's Clinical Trial Finder HERE
CREATE A FREE HEALTHTREE ACCOUNT
about the author
Lisa Foster
Lisa Foster is a mom of 3 daughters, a puzzle lover, writer and HealthTree advocate. She believes in the mission of the foundation and the team that builds it forward. She calls Houston, Texas home.
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.